Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Account Payables
Amounts the company owes suppliers for goods and services received.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 130.1% from a year ago
Account payables stood at $9.65M at the end of Q1 FY2026, up 130.1% from a year earlier and up 18.9% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Account payables amounted to 3.7% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +130.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 8.11M USD
- Year-over-year change
- +78.5%
- 4-year CAGR
- -11.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.11M | +78.5% |
| FY2024 | 2024-12-31 | 4.55M | +20.2% |
| FY2023 | 2023-12-31 | 3.78M | -53.1% |
| FY2022 | 2022-12-31 | 8.07M | -39.3% |
| FY2021 | 2021-12-31 | 13.28M | — |
Account Payables vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +130.1% is the 3rd highest of 10, against a peer median of +7.8%.
- Account payables amounts to 3.7% of total assets for TNXP, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €15.04M EUR | +89.8% | +3.3% | 24.0% | |
| Mar 2026 | $13.08M USD | +160.5% | +105.4% | 19.5% | |
| Mar 2026 | $10.02M USD | +320.4% | +35.6% | 5.2% | |
| Mar 2026 | $9.65M USD | +130.1% | +0.2% | 3.7% | |
| Mar 2026 | $6.59M USD | +127.0% | +18.1% | 4.5% | |
| Mar 2026 | $3.28M USD | -21.8% | -31.5% | 1.2% | |
| Mar 2026 | $2.34M USD | +7.8% | -54.1% | 2.0% | |
| Mar 2026 | $1.59M USD | +6.4% | +5.9% | 0.4% | |
| Mar 2026 | $356K USD | -47.7% | -63.8% | 0.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $272K USD | -93.3% | -37.9% | 1.2% |
| Peer median (excluding TNXP) | — | +7.8% | +3.3% | 2.0% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.66M | 120.23M | 24.95M | 98.78M | 207.64M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 7.73M | 8.04M | 4.59M | 7.9M | 9.76M |
| Inventory | 0 | 0 | 14.15M | 8.41M | 6.01M |
| Other Current Assets | 1.18M | 1.23M | 2.43M | 1.46M | 5.47M |
| Total Current Assets | 189.05M | 130.78M | 47.77M | 119M | 228.88M |
| Property, Plant & Equipment (Net) | 51.47M | 94.53M | 94.85M | 42.82M | 46M |
| Goodwill | 0 | 0 | 965K | 0 | 0 |
| Intangible Assets | 120K | 120K | 9.74M | 120K | 120K |
| Long-term Investments | 240K | 0 | 0 | 904K | 2.18M |
| Tax Assets | (240K) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 259K | 264K | 1.13M | 47K | 0 |
| Total Non-current Assets | 51.85M | 94.91M | 106.69M | 43.89M | 48.3M |
| Total Assets | 240.9M | 225.69M | 154.46M | 162.89M | 277.17M |
| Account Payables | 13.28M | 8.07M | 3.78M | 4.55M | 8.11M |
| Short-term Debt | 0 | 0 | 2.35M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.83M | 3.27M | 2.98M | 1.82M | 3.43M |
| Other Current Liabilities | 2.25M | 3.65M | 5.14M | 7.32M | 11.26M |
| Total Current Liabilities | 21.72M | 18.18M | 18.88M | 18.31M | 30.84M |
| Long-term Debt | 0 | 0 | 6.56M | 4.67M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 22.86M | 0 | 0 |
| Total Non-current Liabilities | 467K | 328K | 30.05M | 5.03M | 1.18M |
| Total Liabilities | 22.18M | 18.51M | 48.93M | 23.33M | 32.02M |
| Common Stock | 496K | 12K | 59K | 4K | 13K |
| Retained Earnings | (359.82M) | (470.04M) | (600.66M) | (730.69M) | (854.72M) |
| Accumulated OCI | (92K) | (167K) | (232K) | (255K) | (289K) |
| Other Stockholders Equity | 480K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 218.72M | 207.18M | 105.53M | 139.56M | 245.15M |
| Total Debt | 956K | 760K | 9.81M | 5.3M | 1.31M |
| Net Debt | (177.7M) | (119.47M) | (15.14M) | (93.48M) | (206.33M) |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.